Myriad's Prolaris® Test Predicts Risk of Prostate Cancer Recurrence in Fourth Peer Reviewed Study
Researchers at the
Following the publication of this study in JCO, Prolaris will have published, peer reviewed data incorporating four major studies and over 1,500 patients. In all four studies, researchers were able to demonstrate the effectiveness of the Prolaris test as a prognostic tool for predicting the risk of recurrence and prostate cancer survival across a variety of tissue formats. Survival and disease recurrence are the gold standard end points for cancer clinical trials and provide the physicians with actionable information that may guide treatment decisions.
"Myriad's Prolaris test is the only test on the market that has consistently demonstrated prognostic value in both pre and post prostatectomy settings," said Jerry Lanchbury Ph.D., Chief Scientific Officer of
Current treatment practice for patients following prostatectomy is to only monitor those patients until biochemical recurrence has occurred. Since no additional treatment such as chemotherapy is typically provided, an aggressive cancer will frequently progress resulting in life threatening metastasis. Approximately 30% of patients will experience cancer recurrence after treatment. Knowing which patients have an increased risk for biochemical recurrence may allow physicians to treat their patients more aggressively in the adjuvant setting with radiation or one of the new chemotherapies specifically targeting prostate cancer.
Prolaris is a genomic risk stratification test developed to aid physicians in predicting prostate cancer aggressiveness in conjunction with clinical parameters such as Gleason score and PSA. Prolaris is a direct molecular measure of prostate cancer tumor biology. By measuring the expression levels of genes involved with cancer proliferation, Prolaris is able to more accurately predict disease progression and enable physicians to better define a treatment/monitoring strategy for their patients. Prolaris has been studied in over 3,000 patients and has consistently demonstrated superior prognostic value than clinical parameters currently used. Prolaris provides unique additional information that can be combined with other clinical factors to make the most accurate prediction of a patient's cancer aggressiveness and therefore disease progression.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the effectiveness of the Prolaris test to stratify men by risk of biochemical recurrence; the ability of the Prolaris test to more accurately predict the risk of prostate cancer recurrence than current clinical parameters used in risk assessment and to help healthcare providers make better informed decisions regarding treatment of patients following radical prostatectomy; the Company's belief that the Prolaris test is the only test on the market that has consistently demonstrated prognostic value in both pre and post prostatectomy settings; the Company's belief that the Prolaris test provides physicians and patients with a better risk assessment tool to predict which men are more likely to have recurrence of their disease
even after undergoing aggressive treatment such as a radical prostatectomy; and the Company's strategic directives under the captions "About Prolaris" and "About Myriad Genetics." These "forward-looking statements" are management's present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or will not continue to increase at historical rates; risks related to changes in the governmental or private insurers reimbursement levels for our tests; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and
companion diagnostic services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and companion diagnostic services, including our ability to successfully generate revenue outside
CONTACT: Investor RelationsSource:
Scott Gleason, Vice President of Investor Relations (801) 584-1143 firstname.lastname@example.org
News Provided by Acquire Media